Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: fullerene based antioxidant therapeutics - Tego BioSciences/Merck

Drug Profile

Research programme: fullerene based antioxidant therapeutics - Tego BioSciences/Merck

Alternative Names: C3

Latest Information Update: 24 Mar 2010

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tego BioSciences
  • Class Fullerenes; Small molecules
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Neurological disorders

Most Recent Events

  • 11 Jul 2007 Fullerene based antioxidant therapeutics are available for partnering (http://www.tegiobio.com)
  • 25 Jun 2007 C Sixty Acquisition Corp is now called Tego BioSciences Corporation
  • 26 Mar 2007 C Sixty Inc has been acquired by Arrowhead Research Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top